Roche has parted with $1.4 billion upfront to secure rights to an obesity candidate developed by Zealand Pharma, taking its ...

Viking Therapeutics (VKTX), the developer of a promising experimental weight-loss drug, has announced a multi-year ...

Morgan Stanley notes Novo Nordisk (NVO) disclosed headline data for CagriSema in REDEFINE-2, with a weight loss and safety profile similar to ...

Novo Nordisk announced launching a direct-to-patient online pharmacy NovoCare, offering a more than half-price cut for its ...

GUB014295 is a subcutaneously administered long-acting amylin agonist that also stimulates calcitonin receptors, according to ...

AbbVie is paying $350 million to join the obesity race. The outlay, plus up to $1.875 billion in milestones, has landed the ...

27 February 2025 The government of Ukraine plans to increase public procurements of drugs this year and to make them more affordable for local population despite the current tough business environment ...

We recently compiled a list of the 20 High Growth Mega Cap Stocks You Can Buy And Hold For Next 5 Years. In this article, we are going to take a look at where Novo Nordisk A/S (NYSE:NVO) stands ...

Besides, last month the Amycretin trial results were released and stock showed an upward hike due to the satisfying results. Even though the drug won’t be available anytime soon as it is still ...

Besides, last month the Amycretin trial results were released and stock showed an upward hike due to the satisfying results. Even though the drug won’t be available anytime soon as it is still ...